Timothy grass pollen-specific Immunoglobulin E (Timothy grass sIgE)

Timothy grass pollen-specific Immunoglobulin E (IgE) refers to the subset of antibodies that recognize and bind to allergens from Phleum pratense and related grasses within the Pooideae subfamily. These antibodies play a central role in the pathogenesis of seasonal allergic rhinitis and asthma by binding to high-affinity FcεRI receptors on mast cells and basophils (Valenta et al., 2019). When an individual is exposed to grass pollen, the allergens cross-link these surface-bound IgE molecules, triggering the immediate release of inflammatory mediators such as histamine, prostaglandins, and leukotrienes. This cascade results in the classic symptoms of hay fever, including sneezing, nasal congestion, and bronchoconstriction. Therapeutic management involves either neutralizing the IgE molecules using biologics like Omalizumab or modifying the immune system's production of these antibodies through allergen-specific immunotherapy (AIT). AIT aims to induce clinical tolerance by promoting the production of 'blocking' IgG4 antibodies and regulatory T cells, thereby reducing the IgE-mediated inflammatory response upon natural allergen exposure (Durham & Shamji, 2023).

Other names

Phleum pratense-specific IgEPooideae grass-specific IgEGrass pollen-specific IgEAnti-Phl p IgEPatient IgE antibodies specific for timothy grass pollen allergens

Omalizumab binds to the Fc region of free circulating IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils, which inhibits the allergic cascade (Bousquet et al., 2001). Allergen immunotherapy (AIT) involves the administration of specific allergen extracts to induce immune tolerance, characterized by a shift from Th2 to Th1/Treg responses and the production of allergen-specific IgG4 'blocking' antibodies that compete with IgE for allergen binding (Durham & Shamji, 2023).